MADDEN SECURITIES Corp Has $1.25 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

MADDEN SECURITIES Corp lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 38.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 13,500 shares of the biopharmaceutical company’s stock after selling 8,340 shares during the period. MADDEN SECURITIES Corp’s holdings in Gilead Sciences were worth $1,247,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Soltis Investment Advisors LLC acquired a new position in shares of Gilead Sciences during the 4th quarter worth $242,000. Wingate Wealth Advisors Inc. bought a new stake in Gilead Sciences in the fourth quarter worth $118,000. Savant Capital LLC increased its position in Gilead Sciences by 2.0% during the fourth quarter. Savant Capital LLC now owns 27,921 shares of the biopharmaceutical company’s stock worth $2,579,000 after buying an additional 558 shares during the last quarter. Wagner Wealth Management LLC raised its holdings in Gilead Sciences by 8.5% during the fourth quarter. Wagner Wealth Management LLC now owns 8,710 shares of the biopharmaceutical company’s stock valued at $805,000 after buying an additional 684 shares in the last quarter. Finally, Angeles Wealth Management LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter worth about $200,000. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 572,824 shares of company stock worth $53,611,715. Corporate insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. Bank of America reissued a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a research note on Tuesday, December 10th. Barclays lifted their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $74.00 to $96.00 in a report on Monday, October 21st. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $74.00 to $84.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. Finally, Wolfe Research assumed coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They set an “outperform” rating and a $110.00 target price for the company. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.39.

Gilead Sciences Stock Down 0.6 %

Shares of GILD stock opened at $95.48 on Tuesday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $100.51. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock has a fifty day moving average price of $93.04 and a 200 day moving average price of $86.86. The stock has a market cap of $118.99 billion, a P/E ratio of 1,060.89, a price-to-earnings-growth ratio of 1.25 and a beta of 0.18.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.